Another deal, cholesterol drug developer Aegerion Pharmaceuticals Inc., priced shares of its IPO far below expectations Friday after twice delaying the offering. It closed up nearly 14 percent, however.

Copyright 2010 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform